ASIT biotech appoints Yves Désiront as new Chairman of the Board of Directors

– BELGIUM, Angleur –  ASIT biotech (BSE: ASIT, EBR: ASIT), a clinical-stage biopharmaceutical company focused on the research and development of breakthrough immunotherapy products for the treatment of allergies, today announced that during the board of directors’ meeting of January 16, 2020, Harry Welten and Jean-Paul Prieels informed the board of directors of their intention to resign as directors at the next general meeting of the company. Mr. Louis Champion, the permanent representative of ZOPAMAVI SAS, also submitted his resignation with immediate effect.

Mr. Yves Désiront, permanent representative of RE FINANCE CONSULTING SA was appointed Chairman of the board of directors in place of Louis Champion, permanent representative of ZOPAMAVI SAS.

The board of directors confirmed the mandate of the management of ASIT biotech to explore during the first semester of 2020 the strategic options to preserve the interests of the creditors and shareholders to the maximum extent possible.

About ASIT biotech

ASIT biotech is a Belgian clinical-stage biopharmaceutical company focused on the research and development of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+’ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness.

For more information: https://www.asitbiotech.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.